Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

As one of the largest vaccine makers, Pfizer has a big part of its business hinging on potential immunization policy changes under the incoming Trump administration. So when vaccine skeptic Robert F.

Pfizer's management team recently announced sales and earnings expectations for 2025. An investment-bank analyst thinks Pfizer stock can shoot about 37% higher in 2025. Pfizer has raised its ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

Pfizer CEO met RFK Jr. and Trump, developed good relationship Trump committed to reforming pharmacy benefit managers, reducing medicine costs Pfizer faces investor pressure over strategy, shares ...

Influenza causes 140,000 to 710,000 hospitalisations and 12,000 to 52,000 deaths in the US every year, as well as economic losses of around $25 billion a year, according to Pfizer.

Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share ...